Quest settles federal claims over VIP Giants access for doctors

Quest Diagnostics (DGX) settled federal claims for $13,014,576 plus interest, resolving allegations of illegal kickbacks to healthcare providers via New York Giants events to induce patient referrals. The settlement covers 2013-2022 and includes a 5-year Corporate Integrity Agreement. The case was initiated by whistleblowers, who will share $2,472,769 of the recovery.

Original reporting
Published Nov 15, 2026, 2:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Quest settles federal claims over VIP Giants access for doctors — source image
Decision brief

The 30-second read

$DGXBearishLow
01

Why it matters

The $13M settlement resolves the allegations without admission of liability but introduces a new expense and may affect future billing practices.

02

Market read

Legal settlement adds a modest liability for Quest Diagnostics, potentially influencing its stock price and prompting sector‑wide compliance reviews.

03

What to watch

Potential for stricter future oversight and additional compliance costs beyond the disclosed settlement.

Relevance 5/10Novelty 5/10Timing: after-hours disclosure

Background

Quest Diagnostics, a major U.S. laboratory testing provider, faced federal allegations of false claims and kickbacks tied to its sponsorship of the New York Giants.

Company-level read

Ticker impact

$DGXBearishMedium confidence
Context

Quest Diagnostics disclosed a $13.0M settlement with the U.S. government over false Medicare and Medicaid claims.

Expected impact

likely modest downward pressure as the market prices in the settlement cost and potential future compliance scrutiny

Evidence & confidence

The amount is material for a mid‑cap health‑care services firm, but the figure is relatively modest and the settlement does not imply ongoing operational disruption.

Market effects

May raise scrutiny on other lab testing firms regarding Medicare/Medicaid billing practices.

Limited to U.S. health‑care services sector.

Minimal; primarily a U.S. regulatory enforcement story.

Counterpoint

The settlement cost is small relative to Quest's cash flow; the market may overreact, presenting a buying opportunity.

Key entities

  • Quest Diagnostics, Inc.

    U.S. laboratory testing company (ticker DGX).

  • U.S. Attorney for the District of New Jersey

    Announced the settlement.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.